Dichlorotetra-μ-isobutyratodirhenium(III): Enhancement of cisplatin action and RBC-stabilizing properties

Anticancer Research

Volumn 27, Issue 4 B, 2007, Pages 2487-2492

  Shtemenko I , Natalia ^a,d   Collery, Philippe ^b   Shtemenko, Alexander ^c  

^a OLES HONCHAR DNIPRO NATIONAL UNIVERSITY   (Ukraine)

^b Polyclinique Maymard   (France)

^c UKRAINIAN STATE UNIVERSITY OF CHEMICAL TECHNOLOGY   (Ukraine)

^d NONE   (Ukraine)

Author keywords

Binuclear cluster; Cisplatin; Erythrocytes; Guerin's carcinoma; Rhenium carboxylate; Tumor growth

Indexed keywords

CISPLATIN; DICHLOROTETRA ISOBUTYRATODIRHENIUM; RHENIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; ERYTHROCYTE; GUERIN TUMOR; HEMOGLOBIN BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; METAL BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG SYNERGISM; ERYTHROCYTES; HEMOGLOBINS; NEOPLASMS, EXPERIMENTAL; ORGANOMETALLIC COMPOUNDS; RATS; RATS, WISTAR;

EID: 34547781297     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Reedijk J: Medicinal application of heavy metal compounds. Curr Opin Chem Biol 3: 236-240, 1999.
2. Eastland GW, Yang G and Thompson T: Studies of rhenium carboxylates as antitumor agents. Part II. Antitumor studies of bis(μ-propionato) diaquotetrabromodirhenium (III) in tumor-bearing mice. Meth Find Exptl Clin Pharmacol 5: 435-438, 1983.
3. Shtemenko AV, Shtemenko NI, Oliynik SA and Zelenuk MA: Lyposome forms of rhenium cluster compounds in models of Haemolytic anemia. In: Metal Ions in Biology and Medicine. John Libbey Eurotext, Paris 7: 558-561, 2002.
4. Shtemenko AV, Zelenuk MA, Shtemenko NI and Verbytska YC: Spectrophotometric investigation of the interaction of rhenium complex compounds with phosphatidylcholine in liposomes. Ukr Biokhim Journal (Ukr) 74: 38-43, 2002 (in Ukrainian).
5. Shtemenko NI, Piroshkova-Patalakh IV and Shtemenko AV: Screening and testing strategy for biological activity of rhenium cluster compounds. In: Metal ions in biology and medicine. John Libbey Eurotext, Paris 6: 616-18, 2000.
6. Oliynik SA, Shtemenko NI and Shtemenko AV: Antihemolytic activity of cluster rhenium complexes with organic ligands. Dopovidi NANU (Ukr) 6: 194-198, 2001 (in Ukrainian).
7. Collery P, Shtemenko N, Shtemenko A, Bourleaud M, Etienne JC, Maymard I and Loriquet P: Supplementation by rhenium compounds instead of iron compounds during the treatment by erythropoeitin of anemia in cancer patients. In: Metal Ions in Biology and Medicine. John Libbey Eurotext, Paris 8: 534-537, 2004.
8. Klucnikov NG: Handbook on Inorganic Synthesis. Moscow. Chemistry Ed., pp. 184-186, 1965 (in Russian).
9. Shtemenko AV and Kotel'nikova AS: Formation of binuclear halogenecarboxylates of rhenium with quadruple metal-to-metal bonds: Isvestiya Acadamy of Sciences of USSR. Chemistry (Rus) 11: 2630-2631, 1980 (in Russian).
10. Shtemenko AV and Bovykin BA: Chemistry of Binuclear Rhenium Clusters. In: Rhenium and Rhenium Alloys. TMS publication, Pensylvania, pp. 189-197, 1997.
11. Munechika NC: United States Patent: 5, 662, 931 September 2, 1997.
12. Taylor SK: Is recombinant human erythropoietin (rh-epo) more than just a treatment of anemia in cancer and chemotherapy? Medical Hypothesis 60: 89-93, 2003.
13. Meerson FZ, Evstigneeva ME and Ustinova EE: Effect of chronic haemolytic anemia on heart contractile function and increase of its resistance to hypoxia. Pat Physiol Exp Therap (Rus) 5: 25-29, 1983 (in Russian).
14. Seelig HS, Berger MR and Keppler BK: Antineoplastic activity of three ruthenium derivatives against chemically induced colorectal carcinoma in rats. J Cancer Res Clin Oncol 118: 195-200, 1992.
15. Kakarkin AJ, Penyuk AA, Pushkar MS and Kakarkina LI: Effect of complex containing antioxydants and enterosorbent on nephro- and urotoxicity of cyclophosphamide in rats with Guerin's carcinoma. Exper Oncol (Ukr) 23: 287-290, 2001 (in Ukrainian).
16. Chekhun VF, Lebed OI, Tryndyak VP, Makovetsky VP, Todor IN and Kulik GI: Structural alterations of plasma membranes of Guerin's carcinoma cells upon the development of resistance to doxorubcine. Exper Oncol (Ukr) 24: 279-283, 2002 (in Ukrainian).
17. Oliynik SA, Shtemenko NI and Shtemenko AV: Antiradical activity of cluster rhenium complexes with organic ligands. Dopovidi NANU (Ukr) 7: 176-180, 2001 (in Ukrainian).
18. Shtemenko AV, Shtemenko NI, Olyinik SA and Zelenuk MA: Liposomal forms of rhenium cluster compounds in models of hemolytic anemia. In: Metal Ions in Biology and Medicine, John Libbey Eurotext. Paris 7: 558-561, 2002.
19. Tavazzi B, Amorini AM, Fazzina G, Di Pierro D, Tuttobene M, Giardina B and Lazzarino G: Oxidative stress induces impairment of human erythrocyte energy metabolism through the oxygen radical-mediated direct activation of AMP-deaminase. Biological Chem 276: 48083-48092, 2001.
20. 2]Cl on the isolated ischaemic-reperfused heart. Fundam Clin Pharmacol 9: 545-553, 1995.
21. 2. Russ Inorg Chem 51: 1014-1019, 2006 (in Russian).
22. Shtemenko N, Gorelaya M and Alexandrova L: Further investigations of influence of rhenium compounds with blood proteins. In: Metal Ions in Biology and Medicine: John Libbey Eurotext, Paris 8: 243-245, 2004.
23. Oliynik SA, Shtemenko NI and Shtemenko AV: Toxicity of rhenium substances: discussion of the problem. Contemp Prob Toxicol (Ukr) 1: 11-14, 2001 (in Ukrainian).
24. Estensen RD, Jordan MM, Wiedmann TS, Galbraith AR, Seele VE and Watternberg IW: Effect of chemopreventive agens on separate stages of progression of benzo{a}pyrene induced lung tumors in A/J mice. Carcinogenesis 25: 197-201, 2004.
25. Lippman SM and Hong WK: Cancer prevention by delay. Clin Cancer Res 8: 314-346, 2002.
26. Kreuser ED, Keppler BK, Berdel WE, Piest A and Thiel E: Synergistic antitumor interactios between newly synthesized ruthenium complexes and cytokines in human colon carcinoma cell lines. Semin Oncology 19: 73-81, 1992.
27. Grinevic I, Mans DRA, Peters GI and Schwartsmann G: Irinotecan and oxaliplatin: an overview of the novel chemptherapeutic options for the treatment of advanced colorectal cancer. Brasil J Med Biol Res 34: 1087-1103, 2001.
28. Wan-Long l, Ding-Guo L, Qiang C and Han-Ming L: Clinical and experimental study of oxaliplatin in treating human gastric carcinoma. World J Gastroenterol 10(19): 2911-2915, 2003.
29. Henke M, Laszig R, Rube C, Schafer U, Haase K-D, Schacher B, Mose S, Beer K, Burger U, Doigherty C and Frommhaid H: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-conrolled trial. Lancet 362: 1255-1260, 2003.
30. Reedijk J: Why does cisplatin reach guanine-N7 with competing S-donor ligands available in the cell? Chem Rev 99: 2499-2510, 1999.
31. Prasad SB and Khynriam D: Cisplatin-induced changes in tissue glutathione level and glutathione-related enzymes in Dalton's lymphoma-bearing mice. In: Metal Ions in Biology and Medicine. John Libbey Eurotext, Paris 8: 368-372, 2004.
32. Prasad SB and Kharbangar A: Cisplatin-mediated biochemical changes in mitochondria in tumor-bearing mice. In: Metal ions in biology and medicine. John Libbey Eurotext, Paris 8: 575-579, 2004.
33. Yurchenko OV, Todor IN, Tryndyak VP, Tregubova NA, Kovtonyuk OV, Slyanik GI, Kulik GI and Chekhun VF: Resistance of Guerin's carcinoma cells to cisplatin: biochemical and morphological aspects. Exp Oncol (Ukr) 25: 64-68, 2003.
34. Fuertes MA, Alonso C and Perez JM: Biochemical modulation of cisplatin mechanisms of action: enchancement of antitumor activity and circumvention of drug resistance. Chem Rev 103(3): 645-662, 2003.
35. Bovykin BA, Omelchenko AM, Shtemenko AV and Chasova EV: The unusual ability of a rhenium (Y) complex containing nicotinamide to raise the conductivity of lipid membranes. Biophysics 40: 525-529, 1995.